These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 22362765)

  • 1. A monoclonal antibody directed against a conformational epitope of the HIV-1 trans-activator (Tat) protein neutralizes cross-clade.
    Mediouni S; Watkins JD; Pierres M; Bole A; Loret EP; Baillat G
    J Biol Chem; 2012 Apr; 287(15):11942-50. PubMed ID: 22362765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a highly conserved surface on Tat variants.
    Mediouni S; Darque A; Ravaux I; Baillat G; Devaux C; Loret EP
    J Biol Chem; 2013 Jun; 288(26):19072-80. PubMed ID: 23678001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tat-neutralizing antibodies in vaccinated macaques.
    Tikhonov I; Ruckwardt TJ; Hatfield GS; Pauza CD
    J Virol; 2003 Mar; 77(5):3157-66. PubMed ID: 12584340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fab'-induced folding of antigenic N-terminal peptides from intrinsically disordered HIV-1 Tat revealed by X-ray crystallography.
    Serrière J; Dugua JM; Bossus M; Verrier B; Haser R; Gouet P; Guillon C
    J Mol Biol; 2011 Jan; 405(1):33-42. PubMed ID: 21035463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tat HIV-1 primary and tertiary structures critical to immune response against non-homologous variants.
    Opi S; Péloponèse JM; Esquieu D; Campbell G; de Mareuil J; Walburger A; Solomiac M; Grégoire C; Bouveret E; Yirrell DL; Loret EP
    J Biol Chem; 2002 Sep; 277(39):35915-9. PubMed ID: 12080071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA immunization with HIV-1 tat mutated in the trans activation domain induces humoral and cellular immune responses against wild-type Tat.
    Caselli E; Betti M; Grossi MP; Balboni PG; Rossi C; Boarini C; Cafaro A; Barbanti-Brodano G; Ensoli B; Caputo A
    J Immunol; 1999 May; 162(9):5631-8. PubMed ID: 10228047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial.
    Ensoli B; Nchabeleng M; Ensoli F; Tripiciano A; Bellino S; Picconi O; Sgadari C; Longo O; Tavoschi L; Joffe D; Cafaro A; Francavilla V; Moretti S; Pavone Cossut MR; Collacchi B; Arancio A; Paniccia G; Casabianca A; Magnani M; Buttò S; Levendal E; Ndimande JV; Asia B; Pillay Y; Garaci E; Monini P;
    Retrovirology; 2016 Jun; 13(1):34. PubMed ID: 27277839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zn2+ binding to cysteine-rich domain of extracellular human immunodeficiency virus type 1 Tat protein is associated with Tat protein-induced apoptosis.
    Misumi S; Takamune N; Ohtsubo Y; Waniguchi K; Shoji S
    AIDS Res Hum Retroviruses; 2004 Mar; 20(3):297-304. PubMed ID: 15117453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reservoir cells no longer detectable after a heterologous SHIV challenge with the synthetic HIV-1 Tat Oyi vaccine.
    Watkins JD; Lancelot S; Campbell GR; Esquieu D; de Mareuil J; Opi S; Annappa S; Salles JP; Loret EP
    Retrovirology; 2006 Jan; 3():8. PubMed ID: 16441880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Codon optimization of the tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization.
    Ramakrishna L; Anand KK; Mohankumar KM; Ranga U
    J Virol; 2004 Sep; 78(17):9174-89. PubMed ID: 15308713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: implications for the design of new vaccination strategies against AIDS.
    Gavioli R; Cellini S; Castaldello A; Voltan R; Gallerani E; Gagliardoni F; Fortini C; Cofano EB; Triulzi C; Cafaro A; Srivastava I; Barnett S; Caputo A; Ensoli B
    Vaccine; 2008 Jan; 26(5):727-37. PubMed ID: 18096278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A universal anti-HIV-1 Tat epitope vaccine that is fully synthetic and self-adjuvanting.
    Goldstein G; Chicca JJ
    Vaccine; 2010 Jan; 28(4):1008-14. PubMed ID: 19931501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The grafting of universal T-helper epitopes enhances immunogenicity of HIV-1 Tat concurrently improving its safety profile.
    Kashi VP; Jacob RA; Shamanna RA; Menon M; Balasiddaiah A; Varghese RK; Bachu M; Ranga U
    PLoS One; 2014; 9(12):e114155. PubMed ID: 25531437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Highly stable oligomerization forms of HIV-1 Tat detected by monoclonal antibodies and requirement of monomeric forms for the transactivating function on the HIV-1 LTR.
    Tosi G; Meazza R; De Lerma Barbaro A; D'Agostino A; Mazza S; Corradin G; Albini A; Noonan DM; Ferrini S; Accolla RS
    Eur J Immunol; 2000 Apr; 30(4):1120-6. PubMed ID: 10760801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tat mutations in an African cohort that do not prevent transactivation but change its immunogenic properties.
    Campbell GR; Senkaali D; Watkins J; Esquieu D; Opi S; Yirrell DL; Kaleebu P; Loret EP
    Vaccine; 2007 Dec; 25(50):8441-7. PubMed ID: 17997200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A monoclonal antibody defines a novel HIV type 1 Tat domain involved in trans-cellular trans-activation.
    Valvatne H; Szilvay AM; Helland DE
    AIDS Res Hum Retroviruses; 1996 May; 12(7):611-9. PubMed ID: 8743086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1 infected patients have antibodies recognizing folded Tat.
    Mediouni S; Baillat G; Darque A; Ravaux I; Loret E
    Infect Disord Drug Targets; 2011 Feb; 11(1):57-63. PubMed ID: 21303342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 Tat-specific IgG antibodies in high-responders target a B-cell epitope in the cysteine-rich domain and block extracellular Tat efficiently.
    Kashi VP; Jacob RA; Paul S; Nayak K; Satish B; Swaminathan S; Satish KS; Ranga U
    Vaccine; 2009 Nov; 27(48):6739-47. PubMed ID: 19744585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epitopes for natural antibodies of human immunodeficiency virus (HIV)-negative (normal) and HIV-positive sera are coincident with two key functional sequences of HIV Tat protein.
    Rodman TC; To SE; Hashish H; Manchester K
    Proc Natl Acad Sci U S A; 1993 Aug; 90(16):7719-23. PubMed ID: 7689227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Full-length HIV-1 Tat protein necessary for a vaccine.
    Opi S; Péloponèse JM; Esquieu D; Watkins J; Campbell G; De Mareuil J; Jeang KT; Yirrell DL; Kaleebu P; Loret EP
    Vaccine; 2004 Aug; 22(23-24):3105-11. PubMed ID: 15297062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.